WO2005024058A3 - Compounds for the treatment of diseases involving cognitive impairment, such as alzheimer’s disease, and methods for identifying such compounds - Google Patents

Compounds for the treatment of diseases involving cognitive impairment, such as alzheimer’s disease, and methods for identifying such compounds Download PDF

Info

Publication number
WO2005024058A3
WO2005024058A3 PCT/EP2004/010172 EP2004010172W WO2005024058A3 WO 2005024058 A3 WO2005024058 A3 WO 2005024058A3 EP 2004010172 W EP2004010172 W EP 2004010172W WO 2005024058 A3 WO2005024058 A3 WO 2005024058A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
methods
cognitive impairment
alzheimer
disease
Prior art date
Application number
PCT/EP2004/010172
Other languages
French (fr)
Other versions
WO2005024058A2 (en
Inventor
Pascal Gerard Merchiers
Koenraad Frederik Fl Spittaels
Marcel Hofmann
Kim Thijs
Wendy Laenen
Original Assignee
Galapagos Genomics Nv
Pascal Gerard Merchiers
Koenraad Frederik Fl Spittaels
Marcel Hofmann
Kim Thijs
Wendy Laenen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics Nv, Pascal Gerard Merchiers, Koenraad Frederik Fl Spittaels, Marcel Hofmann, Kim Thijs, Wendy Laenen filed Critical Galapagos Genomics Nv
Publication of WO2005024058A2 publication Critical patent/WO2005024058A2/en
Publication of WO2005024058A3 publication Critical patent/WO2005024058A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to compounds for use as a medicament in diseases involving cognitive impairment such as Alzheimer’s disease. In particular, the present invention relates to antagonists of and translation inhibitory compounds of the gene encoding FPRL1, FPRL2, FPR1, GPR32, CMKLR1, C5R1, GPR44, GCGR, GLP1R, GLP2R, GIPR, VIPR1, SCTR, VIPR2, providing a reduction of the levels of amyloid-beta protein. The invention further relates to methods for identifying such agonists and translation inhibitory compounds and methods for diagnosing a pathological condition involving cognitive impairment.
PCT/EP2004/010172 2003-09-10 2004-09-10 Compounds for the treatment of diseases involving cognitive impairment, such as alzheimer’s disease, and methods for identifying such compounds WO2005024058A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP03/10160 2003-09-10
PCT/EP2003/010160 WO2005024057A1 (en) 2003-09-10 2003-09-10 Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell

Publications (2)

Publication Number Publication Date
WO2005024058A2 WO2005024058A2 (en) 2005-03-17
WO2005024058A3 true WO2005024058A3 (en) 2005-11-10

Family

ID=34259125

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/010160 WO2005024057A1 (en) 2003-09-10 2003-09-10 Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
PCT/EP2004/010172 WO2005024058A2 (en) 2003-09-10 2004-09-10 Compounds for the treatment of diseases involving cognitive impairment, such as alzheimer’s disease, and methods for identifying such compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010160 WO2005024057A1 (en) 2003-09-10 2003-09-10 Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell

Country Status (2)

Country Link
AU (1) AU2003267347A1 (en)
WO (2) WO2005024057A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002332929A1 (en) 2001-09-07 2003-03-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
KR20060130064A (en) * 2003-11-07 2006-12-18 아카디아 파마슈티칼스 인코포레이티드 Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
US7671028B2 (en) * 2004-02-04 2010-03-02 Postech Foundation Peptides that antagonize FPR class receptor mediated signaling
WO2005103255A1 (en) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Formylpeptide receptor (fpr) as a target for anti-malignant glioma therapy
WO2005103708A1 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor gpr32-like (gpr32-like)
WO2005106490A1 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine-like receptor 1 (cmklr1)
WO2008028250A1 (en) * 2006-09-08 2008-03-13 Autogen Research Pty Ltd Therapeutic agents, targets and diagnostics
CN101586103B (en) * 2009-06-25 2010-12-08 上海交通大学 RNA interference sequence of glucagon receptor gene
CN104258371B (en) * 2014-09-25 2016-06-15 中山大学 WWW tripeptides purposes in preparation treatment Alzheimer disease drug
CN104274817B (en) * 2014-09-25 2016-06-15 中山大学 WRW tripeptides purposes in preparation treatment Alzheimer disease drug

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029052A2 (en) * 2000-10-06 2002-04-11 Bayer Aktiengesellschaft Regulation of human secretin receptor-like gpcr
WO2002044212A2 (en) * 2000-11-30 2002-06-06 Deleersnijder, Willy Human g-protein coupled receptor and uses thereof
WO2003028631A2 (en) * 2001-09-21 2003-04-10 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
WO2003035684A1 (en) * 2001-10-18 2003-05-01 Axaron-Bioscience Ag Ee3-protein family and corresponding dna sequences
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
WO2003065983A2 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003082314A2 (en) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2004010992A1 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2004010936A2 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083553A2 (en) * 2000-05-03 2001-11-08 Pharmacia & Upjohn Company G protein-coupled receptors
AU2003206749A1 (en) * 2002-02-01 2003-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the gpr65 receptor
AU2003214072A1 (en) * 2002-03-07 2003-09-16 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
AU2003218716A1 (en) * 2002-03-22 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with homo sapiens formyl peptide receptor-like 2
US20060165679A1 (en) * 2002-05-08 2006-07-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 2 (vpac2)

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002029052A2 (en) * 2000-10-06 2002-04-11 Bayer Aktiengesellschaft Regulation of human secretin receptor-like gpcr
WO2002044212A2 (en) * 2000-11-30 2002-06-06 Deleersnijder, Willy Human g-protein coupled receptor and uses thereof
WO2003028631A2 (en) * 2001-09-21 2003-04-10 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
WO2003035684A1 (en) * 2001-10-18 2003-05-01 Axaron-Bioscience Ag Ee3-protein family and corresponding dna sequences
WO2003065983A2 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003082314A2 (en) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
WO2004010992A1 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2004010936A2 (en) * 2002-07-30 2004-02-05 Merck & Co., Inc. Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
WO2004094636A1 (en) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AHN J-M ET AL: "DEVELOPMENT OF POTENT GLUCAGON ANTAGONISTS: STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF GLYCINE AT POSITION 4", JOURNAL OF PEPTIDE RESEARCH, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 58, no. 2, 1 August 2001 (2001-08-01), pages 151 - 158, XP001039109, ISSN: 1397-002X *
BAE YOE-SIK ET AL: "Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling", JOURNAL OF IMMUNOLOGY, vol. 173, no. 1, 1 July 2004 (2004-07-01), pages 607 - 614, XP002321867, ISSN: 0022-1767 *
CHANG L L ET AL: "Substituted Imidazoles as Glucagon Receptor Antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 11, no. 18, 17 September 2001 (2001-09-17), pages 2549 - 2553, XP002222313, ISSN: 0960-894X *
GUILLON J ET AL: "Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non-peptide glucagon receptor antagonists", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 33, no. 4, April 1998 (1998-04-01), pages 293 - 308, XP004128204, ISSN: 0223-5234 *
LADOUCEUR G H ET AL: "4-Phenylpyridine glucagon receptor antagonists: synthetic approaches to the sterically hindered chiral hydroxy group", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 43, no. 25, 17 June 2002 (2002-06-17), pages 4455 - 4458, XP004361174, ISSN: 0040-4039 *
LE Y ET AL: "PLEIOTROPIC ROLES OF FORMYL PEPTIDE RECEPTORS", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 12, no. 1, March 2001 (2001-03-01), pages 91 - 105, XP001133719, ISSN: 1359-6101 *
MADSEN P ET AL: "ADVANCES IN NON-PEPTIDE GLUCAGON RECEPTOR ANTAGONISTS", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 5, no. 9, September 1999 (1999-09-01), pages 683 - 691, XP009018759, ISSN: 1381-6128 *
MADSEN PETER ET AL: "Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 26, 17 December 1998 (1998-12-17), pages 5150 - 5157, XP002333263, ISSN: 0022-2623 *
NITSCH R M ET AL: "REGULATION OF PROTEOLYTIC PROCESSING OF THE AMYLOID BETA-PROTEIN PRECURSOR BY FIRST MESSENGERS", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR. AULENDORF, DE, vol. 45, no. 32, 1995, pages 435 - 438, XP002054765, ISSN: 0004-4172 *
PETERSEN K F ET AL: "Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans", DIABETOLOGIA, BERLIN, DE, vol. 44, no. 11, November 2001 (2001-11-01), pages 2018 - 2024, XP002259423, ISSN: 0012-186X *
POST STEVEN R ET AL: "Mechanism of action of des-His-1-(Glu-9)-glucagon amide, a peptide antagonist of the glucagon receptor system", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 90, no. 5, 1993, pages 1662 - 1666, XP002333264, ISSN: 0027-8424 *
YAZAWA HIROSHI ET AL: "beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages", FASEB JOURNAL, vol. 15, no. 13, November 2001 (2001-11-01), pages 2454 - 2462, XP002280686, ISSN: 0892-6638 *

Also Published As

Publication number Publication date
AU2003267347A1 (en) 2005-03-29
WO2005024057A1 (en) 2005-03-17
WO2005024058A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
EP2639301A3 (en) Polynucleotides encoding novel PCSK9 variants
EP1571970A4 (en) Diagnosis and monitoring of diseases
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
MY148086A (en) Antibodies directed against amyloid-beta peptide and methods using same
EP1813947A4 (en) Method of examining alzheimer's disease and diagnostic reagent
HK1117083A1 (en) Compositions and methods for treatment of eye disorders
WO2005024058A3 (en) Compounds for the treatment of diseases involving cognitive impairment, such as alzheimer’s disease, and methods for identifying such compounds
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
EP2287340A3 (en) Method for diagnosis and treatment of a mental disease
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2002086076A3 (en) Polynucleotides and polypeptides associated with the nf-kb pathway
WO2002072751A3 (en) Polynucleotides encoding a metalloprotease, mp-1
WO2009100953A3 (en) Diagnostic method
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
WO2006046270A3 (en) Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof
WO2004100886A3 (en) POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-kB PATHWAY
WO2004083388A3 (en) Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2002083856A3 (en) Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
WO2002057460A3 (en) Polynucleotides encoding human phosphatases
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
WO2003088811A3 (en) Gelsolin as a prognostic marker of artherosclerotic diseases
WO2003069553A3 (en) Method of image analysis
WO2003048316A3 (en) Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase